TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05568342

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Effect of Roy Adaptation-Based Nursing Intervention on Stress, Psychosocial Adjustment and Self-Care Power in Hemodialysis Patients: A Randomized Controlled Experimental Study
Description: Pre-test was applied to the patients in Roy and clinical groups using data collection tools. After the pre-test, the patients in the Roy group were trained 6 times in 3 months, twice a month, at home and in the clinic. Nursing interventions were performed using the Roy Adaptation Model in the trainings. At the end of the third month, the post-test data of both groups were collected. During the study, no training or intervention was given to the patients in the clinical group. The nursing education and interventions of this group were carried out by nurses working in the dialysis clinic within the scope of routine practices.
Study: NCT02837315

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief Motivational Intervention (BMI)
Description: This session includes a discussion related to harm reduction and the student's autonomy to make decisions about the information provided in the session; a marijuana use decisional balance exercise; personalized marijuana-related feedback, and goal-setting. Elements included in the feedback are: (a) comparison of the student's perception of how much college students use marijuana and actual student norms, (b) a comparison of the student's marijuana use vs. norms, (c) drug-related problems experienced, (e) money spent on marijuana, and (f) alcohol norms and consequences if participants indicated they also drink alcohol. Participants discuss the personalized feedback with the clinician and review protective behavioral strategies if she or she indicates interest.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Motivational Intervention (BMI)
Description: This session includes a discussion related to harm reduction and the student's autonomy to make decisions about the information provided in the session; a marijuana use decisional balance exercise; personalized marijuana-related feedback, and goal-setting. Elements included in the feedback are: (a) comparison of the student's perception of how much college students use marijuana and actual student norms, (b) a comparison of the student's marijuana use vs. norms, (c) drug-related problems experienced, (e) money spent on marijuana, and (f) alcohol norms and consequences if participants indicated they also drink alcohol. Participants discuss the personalized feedback with the clinician and review protective behavioral strategies if she or she indicates interest.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Substance-Free Activity Session (SFAS)
Description: The clinician initiates a discussion of the student's college and career goals. Students discuss the values that motivate them as well as how marijuana use may interfere with their ability to accomplish these goals. Students then receive information on graduation rates and income benefits for those who attend and excel in college. They receive personalized feedback on (a) the requirements for their major and intended career, (b) a list of extracurricular activities tailored to their goals, (c) a graph showing time they allocate to their activities, (d) information on stress and depressive symptoms (if applicable) and possible adaptive coping responses and (e) a list of substance-free recreational activities in which they would like to start or continuing engaging.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Relaxation Session
Description: The session includes a clinician-led diaphragmatic breathing exercise, followed by a progressive muscle relaxation protocol (\~30 minutes). At the end of the session, students are asked about their reaction to the relaxation techniques and are provided with relaxation training handouts.
Study: NCT03927105

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab is a human monoclonal antibody (HuMAb; immunoglobulin G4 \[IgG4\]-S228P) that targets the programmed death-1 (PD-1) cluster of differentiation 279 (CD279) cell surface membrane receptor. PD-1 is a negative regulatory molecule expressed by activated T and B lymphocytes.1 Binding of PD-1 to its ligands, programmed death-ligands 1 (PD-L1) and 2 (PD-L2), results in the down-regulation of lymphocyte activation. Inhibition of the interaction between PD-1 and its ligands promotes immune responses and antigen-specific T-cell responses to both foreign antigens as well as self-antigens. Nivolumab will be delivered intravenously at a fixed dose of 240 mg on day 1 of 14 day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cabiralizumab
Description: Cabiralizumab is a recombinant, humanized Immunoglobulin G4 (IgG4) monoclonal antibody that binds to human colony stimulating factor 1 receptor (CSF1R; c-fms). Cabiralizumab will be delivered intravenously at a dosage of 4 mg/kg on day 1 of 14 day cycles.
Study: NCT01436539

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adefovir Dipivoxil and polyene phosphatidylcholine
Description: Adefovir Dipivoxil 10 mg once daily for 48 weeks plus Polyene phosphatidylcholine (PPC) 456 mg three times per day for 48 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adefovir Dipivoxil
Description: Adefovir Dipivoxil 10 mg once daily for 48 weeks
Study: NCT01961700

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Description: Physiotherapy treatment
Study: NCT01536054

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALVAC(2)-NY-ESO-1 (M)/TRICOM vaccine
Description: Given SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sirolimus
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sargramostim
Description: Given SC
Study: NCT01759758

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Plaster Ulnar Gutter Splint
Description: Patients are placed in a plaster ulnar gutter splint, molded in the safe position.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thermoplastic Splint
Description: Thermoplastic Splint is heat moulded to the patient's hand, stabilizing the metacarpal heads, but not immobilizing any joints. This is done by our occupational therapist.
Study: NCT01514682

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-inflammatory Combination Therapy
Description: 1. salsalate: target dose 4 gm/day, administered in two divided doses of 2 gm in the morning and 2 gm in the evening~2. fluvastatin: target dose 40 mg/day, administered in a single evening dose~3. combined omega-3-fatty acid preparation of EPA and DHA; target dose EPA 2 gm/day and DHA 2 gm/day administered in a single evening dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Non-medication pills; To be taken in morning and evening intervals.
Study: NCT04201483

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: DCE without RUSI feedback
Description: Participants assigned to this group will perform an exercise known to selectively activate the semispinalis cervicis muscle

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DCE + RUSI feedback about performance
Description: Participants in this group will perform the same exercise as the DCE group to selectively activate the semispinalis cervicis muscle but receiving RUSI feedback about correct performance
Study: NCT02436850

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thoracentesis
Description: An invasive procedure to remove fluid or air from the pleural space for diagnostic or therapeutic purposes.
Study: NCT05562986

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: GCF (gingival crevicular fluid) collection
Description: Prior to GCF (gingival crevicular fluid) sampling, supragingival plaque was removed by sterile curets and, after air drying, the surfaces were isolated by cotton rolls. Filter paper strips (periopaper, proflow Inc., Amityville, NewYork, USA) were placed in sulcus for 30s. Care was taken not to avoid mechanical trauma and strips contaminated with blood or saliva were discarded. The absorbed GCF volume was estimated by a calibrated instrument (periotron 8000, proflow Inc., Amityville, NY, USA). Then, the strips were sealed into sterile tubes before freezing at -80 0C. The readings were converted to an actual volume (μl) by reference to the standard curve.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: GCF (gingival crevicular fluid) collection
Description: Prior to GCF (gingival crevicular fluid) sampling, supragingival plaque was removed by sterile curets and, after air drying, the surfaces were isolated by cotton rolls. Filter paper strips (periopaper, proflow Inc., Amityville, NewYork, USA) were placed in sulcus for 30s. Care was taken not to avoid mechanical trauma and strips contaminated with blood or saliva were discarded. The absorbed GCF volume was estimated by a calibrated instrument (periotron 8000, proflow Inc., Amityville, NY, USA). Then, the strips were sealed into sterile tubes before freezing at -80 0C. The readings were converted to an actual volume (μl) by reference to the standard curve.
Study: NCT00180310

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: XIENCE V® Everolimus Eluting Coronary Stent
Description: Drug eluting stent implantation stent in the treatment of coronary artery disease.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TAXUS™ EXPRESS2™ Paclitaxel Eluting Coronary Stent
Description: Drug eluting stent implantation stent in the treatment of coronary artery disease
Study: NCT02787850

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CoolSculpting Treatment
Description: The CoolSculpting device will be used to perform treatments.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CoolSculpting Treatment
Description: The CoolSculpting device will be used to perform treatments.
Study: NCT00494091

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus (CCI-779)
Description: 20 mg/m2 IV TEMSR weekly (Japan, n=6)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus (CCI-779)
Description: 25 mg IV TEMSR weekly (all other pts)
Study: NCT03598166

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Septin9
Description: Septin9 is a FDA-approved blood test for colorectal cancer screening
Study: NCT01602692

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tumescent solution with dilute lidocaine and epinephrine
Description: Tumescent Solution containing both dilute lidocaine (0.05%) and dilute epinephrine (1:1,000,000)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tumescent Solution with dilute epinephrine
Description: Tumescent Solution containing dilute epinephrine (1:1,000,000) only
Study: NCT00807755

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Intravenous (IV) on Day 1 of each 21-day cycle, as per dose escalation schedule (dose levels 1 and 2: dose levels 3 and 4). Number of cycles: 6 maximum.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: 80mg/m2, Intravenous on Days 1, 2, 3 of a 21-day cycle (all dose levels). Number of cycles: 6 maximum.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD001
Description: Orally on Days 1-21 of a 21-day cycle, as per dose escalation schedule (dose level 1: 2.5 mg, dose level 2: 5 mg, dose level 3: 5.0 mg, and dose level 4: 10.0 mg). Number of cycles: unlimited (drug taken from Day 1 until progression of disease or unacceptable toxicity).
Study: NCT01863511

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: loop diuretic

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: loop diuretic

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tolvaptan

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ultrafiltration
Study: NCT03368261

Intervention type: OTHER
Group type: OTHER
Intervention: HTAP/ clinical complications in the sickle cell disease
Description: At the inclusion in our study the diagnosis of PAH will be performed by transthoracic Doppler-echocardiograms in a group of 306 children (aged between 8 to 16 years old) with either SS or SC genotype with similar medical caring, to avoid a known selection bias. These patients will be followed during a 3 years longitudinal period. The occurrence of the clinical specific complications associated with SCD (acute chest syndrome, painful vaso occlusive crisis, septicemia and stroke) and the observed mortality rate of our children group, will be compared in patients groups stratified according to the occurrence of PAH. The expression of several molecular and cellular genetic biomarkers potentially associated with this complication will also be studied.
Study: NCT01002378

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib (Stivarga, BAY73-4506)
Description: A single dose of regorafenib will be administered immediately following a high fat breakfast

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib (Stivarga, BAY73-4506)
Description: A single dose of regorafenib will be administered immediately following a low fat breakfast

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib (Stivarga, BAY73-4506)
Description: A single dose of regorafenib will be administered following an overnight fast
Study: NCT02721355

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: GastimunHP
Description: Health food supplement containing specific IgY against urease of H. pylori
Study: NCT02510768

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ELAPR002f
Description: Intradermal implant

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ELAPR002g
Description: Intradermal implant
Study: NCT03799029

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive training
Description: Participants will train at home during 25 sessions (about 45 minutes each) over a maximum of 5 weeks. Investigators will verify compliance via Internet and call participants and their legal guardians once a week. A reward system will be established with participants. Five sessions of metacognition (1 hour each) are added.
Study: NCT02510768

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Intradermal implant
Study: NCT00356278

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-Cycloserine
Description: D-Cycloserine doses will be 50 mg. There will be 5 pills total during study, each given 30 minutes prior to each VRE session.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alprazolam
Description: Alprazolam doses will be 0.25 mg. There will be 5 pills total during study, each given 30 minutes prior to each VRE session.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality Exposure Therapy
Description: VRE includes viewing scenes of virtual Iraq via a head mounted display. Other stimuli presented include sounds, smells and vibration. Each session will be 60 minutes with approximately 30 to 45 minutes of that wearing head mounted display.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Virtual Reality Exposure Therapy
Description: VRE includes viewing scenes of virtual Iraq via a head mounted display. Other stimuli presented include sounds, smells and vibration. Each session will be 60 minutes with approximately 30 to 45 minutes of that wearing head mounted display.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Virtual Reality Exposure Therapy
Description: VRE includes viewing scenes of virtual Iraq via a head mounted display. Other stimuli presented include sounds, smells and vibration. Each session will be 60 minutes with approximately 30 to 45 minutes of that wearing head mounted display.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered in the same manner as the active drugs.
Study: NCT01185405

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Use of different strategy for voriconazole dosage adjustment
Description: Patients will be randomly assigned into 2 groups: conventional adjustment group (CA group) and early adjustment group (EA group). Voriconazole plasma levels will be measured on day 1 (both peak and trough levels), day 3, day 5, day 10, and day 14 (all trough levels). For CA group patients, voriconazole dosage will be adjusted according to the trough levels of day 5 (steady-state level). Predefined dose adjustment protocol will be used (\< 1 µg/ml: 50% increase, 1\~5.5 µg/ml: no change, \> 5.5 µg/ml: 50% decrease). For EA group patients, voriconazole dosage will be adjusted according to the each measurements of voriconazole levels from day 1. Adjusted dosage will be calculated using the NONMEN software.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Use of different strategy for voriconazole dosage adjustment
Description: Patients will be randomly assigned into 2 groups: conventional adjustment group (CA group) and early adjustment group (EA group). Voriconazole plasma levels will be measured on day 1 (both peak and trough levels), day 3, day 5, day 10, and day 14 (all trough levels). For CA group patients, voriconazole dosage will be adjusted according to the trough levels of day 5 (steady-state level). Predefined dose adjustment protocol will be used (\< 1 µg/ml: 50% increase, 1\~5.5 µg/ml: no change, \> 5.5 µg/ml: 50% decrease). For EA group patients, voriconazole dosage will be adjusted according to the each measurements of voriconazole levels from day 1. Adjusted dosage will be calculated using the NONMEN software.
Study: NCT04660162

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Iontophoresis
Description: By using the PeriIont (Perimed, Jarfalla, Sweden) device, 0.5 mL of a 10 mg/ml Sodium nitroprusside solution was used transdermally and ionised with a current strength of 200 µA for 1 minute.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Iontophoresis
Description: By using the PeriIont (Perimed, Jarfalla, Sweden) device, 0.5 mL of a 10 mg/ml Sodium nitroprusside solution was used transdermally and ionised with a current strength of 200 µA for 1 minute.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stepwise occlusion
Description: The upper arm was occluded for 30 seconds with a pneumatic cuff up to 50 mmHg, 80 mmHg, 110 mmHg, 140 mmHg, and 170 mmHg. The volunteer had rest for 5 minutes between each occlusion procedure.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stepwise occlusion
Description: The upper arm was occluded for 30 seconds with a pneumatic cuff up to 50 mmHg, 80 mmHg, 110 mmHg, 140 mmHg, and 170 mmHg. The volunteer had rest for 5 minutes between each occlusion procedure.
Study: NCT05655338

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: antimicrobial photodynamic therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: systemic antibiotics
Study: NCT00647556

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: adapalene gel, 0.3%
Description: applied topically once daily in the evening

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tretinoin 0.05% emollient cream
Description: applied topically once daily in the evening
Study: NCT00599859

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: lactose
Description: consumption of 50g lactose/day in 2 divided doses mixed in water.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: lactose
Description: consumption of lactose 50g/day in 2 divided doses mixed in water
Study: NCT01578980

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Outpatient Control-to-Range
Description: Subjects will spend two nights (\~42 hours) in a local hotel during which the AP Platform will be remotely monitored in an adjacent hotel room for validation that remote system monitoring can successfully occur.
Study: NCT03365466

Intervention type: DRUG
Intervention: Low dose aspirin
Description: LDA 25mg tid

Intervention type: DRUG
Intervention: Low molecular weight heparin
Description: LMWH 5000u IH qd

Intervention type: DRUG
Intervention: Low dose aspirin plus low molecular weight heparin
Description: LDA 25mg tid + LMWH 5000u IH qd

Intervention type: DRUG
Intervention: no treatment
Description: Patients who did not receive any treatment.
Study: NCT04312698

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D013, D326, D337
Description: Experimental: Group 1 Patients assigned to this group are treated with D013, D326, D337

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo of D013, D326, D337
Description: Placebo Comparator: Group 1 Patients assigned to this group are treated with D326, D337, placebo of D013

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: D013, placebo of D326, placebo of D337
Description: Placebo Comparator: Group 2 Patients assigned to this group are treated with D013, placebo of D326, placebo of D337
Study: NCT04316585

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2982772
Description: GSK2982772 will be available as MR tablet at a unit dose strength of 480 mg.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: GSK2982772 matching placebo tablets will be administered via the oral route.
Study: NCT02602730

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Break the Chain
Description: Internet-based smoking cessation intervention designed for general population smokers with targeted materials for pregnant women. The program included a digital coaching component delivered via email at specific points as the user progresses through his/her quit process. Program content is based on Department of Health and Human Services Clinical Practice Guidelines for Treating Tobacco Use and Dependence.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Clearing the Air
Description: PDF version of smoking cessation booklet from National Cancer Institute.
Study: NCT03424759

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9291
Description: Patients will be treated 80 mg/day of AZD9291 orally (1 cycle for 21 days).
Study: NCT01315379

Intervention type: BEHAVIORAL
Intervention: Prolonged Exposure Therapy
Description: This intervention comprises 12-18 sessions of cognitive behavior therapy for PTSD with the components (a) Psychological education, (b) in vivo exposure (c) prolonged imaginal exposure, (d) cognitive restructuring (e) summary and relapse prevention.

Intervention type: BEHAVIORAL
Intervention: Prolonged Exposure Therapy
Description: This intervention comprises 12-18 sessions of cognitive behavior therapy for PTSD with the components (a) Psychological education, (b) in vivo exposure (c) prolonged imaginal exposure, (d) cognitive restructuring (e) summary and relapse prevention.
Study: NCT05654844

Intervention type: RADIATION
Group type: OTHER
Intervention: LC images
Description: Angular and Linear Measurements were compared in mandibular symphysis region using the LC images

Intervention type: RADIATION
Group type: OTHER
Intervention: CBCT images
Description: Angular and Linear Measurements were compared in mandibular symphysis region using the CBCT images